DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for ...
Do not receive XIAFLEX® if you have had an allergic reaction to collagenase clostridium histolyticum or any of the ingredients in XIAFLEX ®, or to any other collagenase product. Please note that, ...
MALVERN, Pa., Nov. 20, 2024 /CNW/ -- Endo, Inc. ("Endo") (OTCQX: NDOI) announced today that John Elway will share an update about his Dupuytren's contracture patient journey, including his treatment ...
DUBLIN, June 5, 2023 /PRNewswire/ -- Endo International plc (ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH, injection ...
DUBLIN, Jan. 21, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that it reached a milestone: 100,000 patients with Peyronie's disease (PD) have been prescribed XIAFLEX® (collagenase ...
In a large, head-to-head trial pitting collagenase injections against limited fasciotomy as treatments for Dupuytren's contracture, the knife won. In the open-label trial, self-reported hand health ...
Campaign builds on the momentum of Endo's disease awareness efforts. Commercial features a real patient—who was an untreated patient in a prior Endo video series—and his wife, sharing their personal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results